Carolina de Oliveira Cruz Latorraca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina de Oliveira Cruz Latorraca has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Isabela Porto de Toledo
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
8 shared publications - Rachel Riera
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil; Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp), São Paulo - SP, Brazil
8 shared publications - Rafael Leite Pacheco
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil; Centro Universitário São Camilo (CUSC), São Paulo - SP, Brazil
8 shared publications - Roberta Borges Silva
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
8 shared publications - Verônica Colpani
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
8 shared publications - Camila Monteiro Cruz
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
7 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (2) , 59-69
The effects of Givinostat for Duchenne muscular dystrophy: a systematic review
Introduction: Givinostat, a histone deacetylase inhibitor, has been investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and slow muscle degradation. DMD is a genetic neuromuscular degenerative disease that begins in early childhood. It is an X-linked recessive disorder characterized by mutations in the dystrophin gene and progressive and severe muscle weakness and atrophy are the main characteristics of this disease. DMD predominantly affects boys, while most females are asymptomatic carriers, with a global prevalence estimated at 19.8 cases per 100,000 live male births. Objective: To evaluate the efficacy and safety of Givinostat for individuals with DMD based on evidence from randomized controlled trials (RCTs). Methodology: We conducted a systematic review following PRISMA guidance, focusing on RCTs assessing Givinostat versus placebo, standard care, no treatment, or any active pharmacological intervention in DMD. CENTRAL, MEDLINE, Embase, PEDro and LILACS were searched (August 2025) without restrictions. Two reviewers independently selected studies, extracted data, and appraised risk of bias using the original Cochrane tool. Certainty of evidence was assessed using GRADE. The protocol was prospectively registered in the PROSPERO database (CRD420251107551). Results: Two RCTs were included, although one is still ongoing. EPIDYS (n=179) compared Givinostat (13 mg to 47 mg twice daily) with placebo for 72 weeks. There is uncertainty regarding the effects of Givinostat on global symptom assessment (mean difference [MD] 1.91; 95% CI 0.30 to 3.53; n=120; very low certainty), serious adverse events (risk ratio [RR] 2.07; 95% CI 0.45 to 9.44; n=179; very low certainty), functional capacity assessed by two different instruments (n=120; very low certainty), and quality of life (MD 3.70; 95% CI −2.30 to 9.70; n=120; very low certainty). Givinostat may have little or no effect on the risk of any adverse events (RR 1.02; 95% CI 0.94 to 1.10; n=179; low certainty). Conclusions: Current evidence on the efficacy of Givinostat remains uncertain, while it may have little or no effect on the risk of any adverse events. Further well-designed RCTs with larger sample sizes and varying disease stages are needed to reduce these uncertainties.
- 31 October 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (2) , 59-69
Open AccessThe effects of Givinostat for Duchenne muscular dystrophy: a systematic review
Introduction: Givinostat, a histone deacetylase inhibitor, has been investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and slow muscle degradation. DMD is a genetic neuromuscular degenerative disease that begins in early childhood. It is an X-linked recessive disorder characterized by mutations in the dystrophin gene and progressive and severe muscle weakness and atrophy are the main characteristics of this disease. DMD predominantly affects boys, while most females are asymptomatic carriers, with a global prevalence estimated at 19.8 cases per 100,000 live male births. Objective: To evaluate the efficacy and safety of Givinostat for individuals with DMD based on evidence from randomized controlled trials (RCTs). Methodology: We conducted a systematic review following PRISMA guidance, focusing on RCTs assessing Givinostat versus placebo, standard care, no treatment, or any active pharmacological intervention in DMD. CENTRAL, MEDLINE, Embase, PEDro and LILACS were searched (August 2025) without restrictions. Two reviewers independently selected studies, extracted data, and appraised risk of bias using the original Cochrane tool. Certainty of evidence was assessed using GRADE. The protocol was prospectively registered in the PROSPERO database (CRD420251107551). Results: Two RCTs were included, although one is still ongoing. EPIDYS (n=179) compared Givinostat (13 mg to 47 mg twice daily) with placebo for 72 weeks. There is uncertainty regarding the effects of Givinostat on global symptom assessment (mean difference [MD] 1.91; 95% CI 0.30 to 3.53; n=120; very low certainty), serious adverse events (risk ratio [RR] 2.07; 95% CI 0.45 to 9.44; n=179; very low certainty), functional capacity assessed by two different instruments (n=120; very low certainty), and quality of life (MD 3.70; 95% CI −2.30 to 9.70; n=120; very low certainty). Givinostat may have little or no effect on the risk of any adverse events (RR 1.02; 95% CI 0.94 to 1.10; n=179; low certainty). Conclusions: Current evidence on the efficacy of Givinostat remains uncertain, while it may have little or no effect on the risk of any adverse events. Further well-designed RCTs with larger sample sizes and varying disease stages are needed to reduce these uncertainties.
- Open Access
- 10 September 2026
- Published by Springer Nature in BMC Neurology
Efficacy and safety of transcranial Direct Current Stimulation (tDCS) in Alzheimer’s disease: systematic review and meta-analysis
- 10 September 2026
- Published by Springer Nature in BMC Neurology
Open AccessEfficacy and safety of transcranial Direct Current Stimulation (tDCS) in Alzheimer’s disease: systematic review and meta-analysis
- Open Access
- 6 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- p. 59-69
The effects of Givinostat for Duchenne muscular dystrophy: a systematic review
Introduction: Givinostat, a histone deacetylase inhibitor, has been investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and slow muscle degradation. DMD is a genetic neuromuscular degenerative disease that begins in early childhood. It is an X-linked recessive disorder characterized by mutations in the dystrophin gene and progressive and severe muscle weakness and atrophy are the main characteristics of this disease. DMD predominantly affects boys, while most females are asymptomatic carriers, with a global prevalence estimated at 19.8 cases per 100,000 live male births. Objective: To evaluate the efficacy and safety of Givinostat for individuals with DMD based on evidence from randomized controlled trials (RCTs). Methodology: We conducted a systematic review following PRISMA guidance, focusing on RCTs assessing Givinostat versus placebo, standard care, no treatment, or any active pharmacological intervention in DMD. CENTRAL, MEDLINE, Embase, PEDro and LILACS were searched (August 2025) without restrictions. Two reviewers independently selected studies, extracted data, and appraised risk of bias using the original Cochrane tool. Certainty of evidence was assessed using GRADE. The protocol was prospectively registered in the PROSPERO database (CRD420251107551). Results: Two RCTs were included, although one is still ongoing. EPIDYS (n=179) compared Givinostat (13 mg to 47 mg twice daily) with placebo for 72 weeks. There is uncertainty regarding the effects of Givinostat on global symptom assessment (mean difference [MD] 1.91; 95% CI 0.30 to 3.53; n=120; very low certainty), serious adverse events (risk ratio [RR] 2.07; 95% CI 0.45 to 9.44; n=179; very low certainty), functional capacity assessed by two different instruments (n=120; very low certainty), and quality of life (MD 3.70; 95% CI −2.30 to 9.70; n=120; very low certainty). Givinostat may have little or no effect on the risk of any adverse events (RR 1.02; 95% CI 0.94 to 1.10; n=179; low certainty). Conclusions: Current evidence on the efficacy of Givinostat remains uncertain, while it may have little or no effect on the risk of any adverse events. Further well-designed RCTs with larger sample sizes and varying disease stages are needed to reduce these uncertainties.
- 6 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- p. 59-69
Open AccessThe effects of Givinostat for Duchenne muscular dystrophy: a systematic review
Introduction: Givinostat, a histone deacetylase inhibitor, has been investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and slow muscle degradation. DMD is a genetic neuromuscular degenerative disease that begins in early childhood. It is an X-linked recessive disorder characterized by mutations in the dystrophin gene and progressive and severe muscle weakness and atrophy are the main characteristics of this disease. DMD predominantly affects boys, while most females are asymptomatic carriers, with a global prevalence estimated at 19.8 cases per 100,000 live male births. Objective: To evaluate the efficacy and safety of Givinostat for individuals with DMD based on evidence from randomized controlled trials (RCTs). Methodology: We conducted a systematic review following PRISMA guidance, focusing on RCTs assessing Givinostat versus placebo, standard care, no treatment, or any active pharmacological intervention in DMD. CENTRAL, MEDLINE, Embase, PEDro and LILACS were searched (August 2025) without restrictions. Two reviewers independently selected studies, extracted data, and appraised risk of bias using the original Cochrane tool. Certainty of evidence was assessed using GRADE. The protocol was prospectively registered in the PROSPERO database (CRD420251107551). Results: Two RCTs were included, although one is still ongoing. EPIDYS (n=179) compared Givinostat (13 mg to 47 mg twice daily) with placebo for 72 weeks. There is uncertainty regarding the effects of Givinostat on global symptom assessment (mean difference [MD] 1.91; 95% CI 0.30 to 3.53; n=120; very low certainty), serious adverse events (risk ratio [RR] 2.07; 95% CI 0.45 to 9.44; n=179; very low certainty), functional capacity assessed by two different instruments (n=120; very low certainty), and quality of life (MD 3.70; 95% CI −2.30 to 9.70; n=120; very low certainty). Givinostat may have little or no effect on the risk of any adverse events (RR 1.02; 95% CI 0.94 to 1.10; n=179; low certainty). Conclusions: Current evidence on the efficacy of Givinostat remains uncertain, while it may have little or no effect on the risk of any adverse events. Further well-designed RCTs with larger sample sizes and varying disease stages are needed to reduce these uncertainties.
- Open Access
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 7-18
Inebilizumab for neuromyelitis optica spectrum disorder: a systematic review
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, immune-mediated inflammatory disease of the central nervous system associated with severe disability and a relapsing course. Inebilizumab, a humanized anti-CD19 monoclonal antibody, was developed to prevent relapses in NMOSD. This systematic review aims to evaluate the efficacy and safety of inebilizumab in adults with NMOSD, regardless of aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus. Methods: We conducted a systematic review of randomized controlled trials (RCTs) in accordance with the Cochrane Handbook and reported using PRISMA 2020. We searched MEDLINE, EMBASE, CENTRAL, LILACS, ClinicalTrials.gov, WHO-ICTRP, and additional sources without restrictions. Eligible trials compared inebilizumab with placebo, no treatment, or active comparators. Outcomes included relapse, disability, visual acuity, NMOSD-related hospitalizations, and adverse events. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence using the GRADE approach. Results: We included two RCTs: one ongoing (NCT07010302) and one published trial (N-MOmentum; n = 230) comparing inebilizumab 300 mg with placebo. Inebilizumab probably reduces time to relapse (hazard ratio 0.27; 95% confidence interval [CI] 0.15–0.50; moderate certainty of evidence), NMOSD-related hospitalizations (risk ratio [RR] 0.40; 95% CI 0.17–0.97; moderate certainty of evidence), and disability worsening (RR 0.46; 95% CI 0.28–0.76; moderate certainty of evidence). Effects on serious adverse events are uncertain (very low evidence certainty). We observed little or no difference in the risk of any adverse events and in visual acuity (low evidence certainty). Conclusions: Inebilizumab probably reduces time to relapse, disability worsening, and disease-related hospitalizations in NMOSD. However, uncertainty remains regarding safety outcomes, and further trials with longer follow-up are required to better characterize the long-term efficacy and safety.
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 7-18
Open AccessInebilizumab for neuromyelitis optica spectrum disorder: a systematic review
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, immune-mediated inflammatory disease of the central nervous system associated with severe disability and a relapsing course. Inebilizumab, a humanized anti-CD19 monoclonal antibody, was developed to prevent relapses in NMOSD. This systematic review aims to evaluate the efficacy and safety of inebilizumab in adults with NMOSD, regardless of aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus. Methods: We conducted a systematic review of randomized controlled trials (RCTs) in accordance with the Cochrane Handbook and reported using PRISMA 2020. We searched MEDLINE, EMBASE, CENTRAL, LILACS, ClinicalTrials.gov, WHO-ICTRP, and additional sources without restrictions. Eligible trials compared inebilizumab with placebo, no treatment, or active comparators. Outcomes included relapse, disability, visual acuity, NMOSD-related hospitalizations, and adverse events. Risk of bias was assessed using the Cochrane tool, and the certainty of evidence using the GRADE approach. Results: We included two RCTs: one ongoing (NCT07010302) and one published trial (N-MOmentum; n = 230) comparing inebilizumab 300 mg with placebo. Inebilizumab probably reduces time to relapse (hazard ratio 0.27; 95% confidence interval [CI] 0.15–0.50; moderate certainty of evidence), NMOSD-related hospitalizations (risk ratio [RR] 0.40; 95% CI 0.17–0.97; moderate certainty of evidence), and disability worsening (RR 0.46; 95% CI 0.28–0.76; moderate certainty of evidence). Effects on serious adverse events are uncertain (very low evidence certainty). We observed little or no difference in the risk of any adverse events and in visual acuity (low evidence certainty). Conclusions: Inebilizumab probably reduces time to relapse, disability worsening, and disease-related hospitalizations in NMOSD. However, uncertainty remains regarding safety outcomes, and further trials with longer follow-up are required to better characterize the long-term efficacy and safety.
- Open Access
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 41-51
Omaveloxolone for Friedreich Ataxia: a systematic review
Background: Friedreich ataxia (FA) is a progressive neurodegenerative disorder with significant morbidity and no established disease-modifying therapies. Omaveloxolone, a novel activator of the Nrf2 pathway, targets core disease mechanisms, yet prior evidence relies on non-randomized or early-phase studies. This systematic review aims to evaluate the efficacy and safety of omaveloxolone for individuals with FA based on evidence from randomized controlled trials (RCTs). Methods: We conducted a systematic review in accordance with the Cochrane Handbook and reported it following the PRISMA 2020. The protocol was prospectively registered in PROSPERO (CRD420251115635). Eligible RCTs compared omaveloxolone versus placebo or standard care in genetically confirmed FA. Only RCTs evaluating the approved dose of omaveloxolone (150 mg/day) were considered for the primary analysis. We performed systematic searches across 7 databases and two clinical trial registers without language or date restrictions. Two review authors independently screened titles and abstracts, extracted data, assessed risk of bias using the Cochrane tool, and evaluated the certainty of evidence using the GRADE framework. Results: We identified three RCTs; however, only one multicenter, phase II, double-blind trial (103 participants aged 16–40 years) evaluated the marketed dose and reported complete 48-week results. Low-certainty evidence indicates that omaveloxolone provides little to no improvement in neurological severity (MD –2.40; 95% CI –4.24 to –0.56) and may increase the risk of serious adverse events (RR 1.75; 95% CI 0.43–6.75), while probably having little or no effect on the risk of any adverse events (RR 1.00; 95% CI 0.96–1.04). Omaveloxolone shows minimal to no effects on dexterity, gait speed, or activities of daily living. Conclusion: Based on the current limited evidence from RCTs, omaveloxolone appears to offer minimal clinical benefit for neurological function and daily activities in FA, with uncertainty surrounding the risk of serious adverse events. Larger, long-term trials are needed to better define the role of omaveloxolone in the management of Friedreich ataxia.
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 41-51
Open AccessOmaveloxolone for Friedreich Ataxia: a systematic review
Background: Friedreich ataxia (FA) is a progressive neurodegenerative disorder with significant morbidity and no established disease-modifying therapies. Omaveloxolone, a novel activator of the Nrf2 pathway, targets core disease mechanisms, yet prior evidence relies on non-randomized or early-phase studies. This systematic review aims to evaluate the efficacy and safety of omaveloxolone for individuals with FA based on evidence from randomized controlled trials (RCTs). Methods: We conducted a systematic review in accordance with the Cochrane Handbook and reported it following the PRISMA 2020. The protocol was prospectively registered in PROSPERO (CRD420251115635). Eligible RCTs compared omaveloxolone versus placebo or standard care in genetically confirmed FA. Only RCTs evaluating the approved dose of omaveloxolone (150 mg/day) were considered for the primary analysis. We performed systematic searches across 7 databases and two clinical trial registers without language or date restrictions. Two review authors independently screened titles and abstracts, extracted data, assessed risk of bias using the Cochrane tool, and evaluated the certainty of evidence using the GRADE framework. Results: We identified three RCTs; however, only one multicenter, phase II, double-blind trial (103 participants aged 16–40 years) evaluated the marketed dose and reported complete 48-week results. Low-certainty evidence indicates that omaveloxolone provides little to no improvement in neurological severity (MD –2.40; 95% CI –4.24 to –0.56) and may increase the risk of serious adverse events (RR 1.75; 95% CI 0.43–6.75), while probably having little or no effect on the risk of any adverse events (RR 1.00; 95% CI 0.96–1.04). Omaveloxolone shows minimal to no effects on dexterity, gait speed, or activities of daily living. Conclusion: Based on the current limited evidence from RCTs, omaveloxolone appears to offer minimal clinical benefit for neurological function and daily activities in FA, with uncertainty surrounding the risk of serious adverse events. Larger, long-term trials are needed to better define the role of omaveloxolone in the management of Friedreich ataxia.
- Open Access
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 32-40
Use of indirect comparison in technology assessment in Brazilian supplementary health: meta-research
Introduction: Technologies already covered in health systems are the ideal comparators in the HTA process of new technologies, making a particular local challenge the finding of these specific head-to-head studies. In their absence, indirect comparisons are presented as alternatives, but the extent and characteristics of use are unknown. Objective: This study aims to quantify the use and characteristics of indirect comparison methods in reports of a Brazilian HTA agency. Methodology: A meta-research was conducted to analyze the frequency of use of different indirect comparison methods from the perspective of Brazil’s supplementary health system, and characteristics such as frequency of incorporation and preliminary recommendation, type of method, certainty-of-evidence assessment tool used, technology type, major clinical area, and budget impact of incorporation. The protocol was registered prospectively and is available at https://doi.org/10.17605/OSF.IO/3V8YP. Results: Indirect comparison methods are used in approximately 28% (23/81) of all HTA for incorporation into Brazil’s supplementary health system, and it is more frequently used in oncology and medicine assessments. Network meta-analysis is the most frequently adopted method [78% (18/23)], but specific frameworks for assessing the certainty of the evidence, such as GRADE-NMA 4% (1/23) and CINeMA 13% (3/23), were rarely used. As for incremental budget impact, it was lower in the HTA that used any type of indirect comparisons. Other agencies are facing an increase in indirect comparison for health technology assessment. Conclusions: Further efforts are necessary to evaluate the impact of indirect comparisons on recommendations and to better standardize the methodological approaches to indirect comparisons.
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 32-40
Open AccessUse of indirect comparison in technology assessment in Brazilian supplementary health: meta-research
Introduction: Technologies already covered in health systems are the ideal comparators in the HTA process of new technologies, making a particular local challenge the finding of these specific head-to-head studies. In their absence, indirect comparisons are presented as alternatives, but the extent and characteristics of use are unknown. Objective: This study aims to quantify the use and characteristics of indirect comparison methods in reports of a Brazilian HTA agency. Methodology: A meta-research was conducted to analyze the frequency of use of different indirect comparison methods from the perspective of Brazil’s supplementary health system, and characteristics such as frequency of incorporation and preliminary recommendation, type of method, certainty-of-evidence assessment tool used, technology type, major clinical area, and budget impact of incorporation. The protocol was registered prospectively and is available at https://doi.org/10.17605/OSF.IO/3V8YP. Results: Indirect comparison methods are used in approximately 28% (23/81) of all HTA for incorporation into Brazil’s supplementary health system, and it is more frequently used in oncology and medicine assessments. Network meta-analysis is the most frequently adopted method [78% (18/23)], but specific frameworks for assessing the certainty of the evidence, such as GRADE-NMA 4% (1/23) and CINeMA 13% (3/23), were rarely used. As for incremental budget impact, it was lower in the HTA that used any type of indirect comparisons. Other agencies are facing an increase in indirect comparison for health technology assessment. Conclusions: Further efforts are necessary to evaluate the impact of indirect comparisons on recommendations and to better standardize the methodological approaches to indirect comparisons.
- Open Access
- 2 July 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (11) , 1339-1349
Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review
Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism‐diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
- 2 July 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (11) , 1339-1349
Open AccessTherapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review
Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism‐diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (10)
Beta-blockers for preventing anthracycline-induced cardiotoxicity: a systematic review with network meta-analysis
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (10)
Open AccessBeta-blockers for preventing anthracycline-induced cardiotoxicity: a systematic review with network meta-analysis